Avalon Investment & Advisory’s Supernus Pharmaceuticals SUPN Stock Holding History

Avalon Investment & Advisory’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-67,899	Closed	-$3.42M	–	353
2018 Q3	$3.42M	Buy	67,899 +4,824	+8%	+$238K	0.1%	191
2018 Q2	$3.77M	Buy	63,075 +25,786	+69%	+$1.34M	0.11%	167
2018 Q1	$1.71M	Buy	37,289 +3,525	+10%	+$147K	0.05%	225
2017 Q4	$1.34M	Buy	33,764 +1,132	+3%	+$44.7K	0.04%	234
2017 Q3	$1.3M	Sell	32,632 -247	-0.8%	-$10.7K	0.04%	224
2017 Q2	$1.42M	Buy	32,879 +4,114	+14%	+$146K	0.05%	218
2017 Q1	$900K	Buy	+28,765	New	+$771K	0.03%	258

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Avalon Investment & Advisory's SUPN Position: Q4 2018 in Review

Avalon Investment & Advisory sold out of Supernus Pharmaceuticals (SUPN) in Q4 2018, closing a stake of 67,899 shares — an estimated $3.42M sold.

Avalon Investment & Advisory first reported a position in SUPN in Q1 2017 and held it in 7 quarters. The position peaked at $3.77M in Q2 2018. 274 funds tracked by Wall St. Rank hold SUPN as of Q4 2018.

Avalon Investment & Advisory reported no remaining Supernus Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
Avalon Investment & Advisory sold 67,899 Supernus Pharmaceuticals shares in Q4 2018, an estimated $3.42M.
Avalon Investment & Advisory first reported a position in Supernus Pharmaceuticals in Q1 2017 and held it in 7 quarters.
Avalon Investment & Advisory's Supernus Pharmaceuticals position peaked at $3.77M in Q2 2018.
274 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q4 2018.

Based on Avalon Investment & Advisory's 13F filing for Q4 2018, filed 14 Feb 2019.